Inoue Y, Bode B P, Beck D J, Li A P, Bland K I, Souba W W
Department of Surgery, University of Florida College of Medicine, Gainesville.
Ann Surg. 1993 Sep;218(3):350-62; discussion 362-3. doi: 10.1097/00000658-199309000-00014.
Arginine transport was characterized and studied in human liver.
Plasma arginine uptake may regulate hepatocyte intracellular availability and the subsequent biosynthesis of nitric oxide (NO), but little is known about arginine transport across the human hepatocyte plasma membrane.
The authors characterized plasma membrane transport of 3[H]-L-arginine in hepatic plasma membrane vesicles (HPMVs) and in hepatocytes isolated and cultured from human liver biopsy specimens. They also studied the effects of the NO synthase inhibitors omega-nitro-L-arginine methyl ester (L-NAME) and N-methyl-arginine (NMA) on arginine transport in HPMVs and in cultured cells.
Arginine transport was saturable, Na(+)-independent, temperature and pH sensitive, and was inhibited by the naturally occurring amino acids lysine, homoarginine, and ornithine (System y+ substrates). Arginine transport by both vesicles and cultured hepatocytes was significantly attenuated by NO synthase inhibitors, suggesting that the arginine transporter and the NO synthase enzyme may share a structurally similar arginine binding site. Dixon plot analysis showed the blockade to occur by competitive, rather than noncompetitive, inhibition. In vivo treatment of rats with lipopolysaccharide (LPS) resulted in a twofold stimulation of saturable arginine transport in the liver. This LPS-induced hepatic arginine transport activity was also inhibited by L-NAME. These data indicate that arginine transport by human hepatocytes is mediated primarily by the Na(+)-independent transport System y+.
Besides inhibition of the NO synthase enzyme, the ability of arginine derivatives to block NO production may also be due to their ability to competitively inhibit arginine transport across the hepatocyte plasma membrane. The use of selective arginine derivatives that compete with arginine at the plasma membrane level may be a metabolic strategy that can be used to modulate the septic response.
对人肝脏中的精氨酸转运进行特性分析和研究。
血浆精氨酸摄取可能调节肝细胞内精氨酸的可利用性以及随后一氧化氮(NO)的生物合成,但关于精氨酸跨人肝细胞质膜的转运情况却知之甚少。
作者对肝细胞质膜囊泡(HPMV)以及从人肝活检标本中分离培养的肝细胞中3[H]-L-精氨酸的质膜转运进行了特性分析。他们还研究了一氧化氮合酶抑制剂ω-硝基-L-精氨酸甲酯(L-NAME)和N-甲基-精氨酸(NMA)对HPMV和培养细胞中精氨酸转运的影响。
精氨酸转运具有饱和性、不依赖Na(+)、对温度和pH敏感,并受到天然存在的氨基酸赖氨酸、高精氨酸和鸟氨酸(系统y+底物)的抑制。囊泡和培养的肝细胞对精氨酸的转运均被一氧化氮合酶抑制剂显著减弱,这表明精氨酸转运体和一氧化氮合酶可能共享一个结构相似的精氨酸结合位点。Dixon作图分析表明这种阻断是由竞争性抑制而非非竞争性抑制引起的。用脂多糖(LPS)对大鼠进行体内处理导致肝脏中可饱和精氨酸转运增加两倍。这种LPS诱导的肝脏精氨酸转运活性也被L-NAME抑制。这些数据表明人肝细胞的精氨酸转运主要由不依赖Na(+)的转运系统y+介导。
除了抑制一氧化氮合酶外,精氨酸衍生物阻断NO生成的能力也可能归因于它们竞争性抑制精氨酸跨肝细胞质膜转运的能力。使用在质膜水平与精氨酸竞争的选择性精氨酸衍生物可能是一种可用于调节脓毒症反应的代谢策略。